APO Research
Talk to an analyst

APO RESEARCH · REPORT

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF)

Compare research editions
View pricing & licenses

Selected research

Industry Research

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026

28 December 2025132 pages

Choose your research edition.

Industry ResearchLong-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032190 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Outlook and Growth Opportunities 2026201 pages · $4,250 USDMarket Analysis & ForecastGlobal Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.

The North America market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.

The Europe market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.

Read the full market overview

The Asia Pacific market for Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.

Leading global manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) include Amgen, Mylan, Kashiv BioSciences, Pfizer, Fresenius Kabi, Coherus BioSciences, Sandoz, Italfarmaco SpA and Evive Biotech, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).

The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.

Key Companies & Market Share Insights

This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market by Company

Amgen

Mylan

Kashiv BioSciences

Pfizer

Fresenius Kabi

Coherus BioSciences

Sandoz

Italfarmaco SpA

Evive Biotech

Chugai Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Amoytop Biotech

Qilu Pharmaceutical

CSPC Baike Biopharma

SL Pharm

Lunan Pharmaceutical

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Type

Lenograstim

Pegfilgrastim

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Application

Hospital and Clinic

Pharmacy

Other

Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;

Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3: Detailed analysis of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.

Chapter 5: Production/output, value of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.

Chapter 6: Consumption of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.

Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 11: The main points and conclusions of the report.

More report detail

Tables and figures
List of Tables Table 1. Secondary Sources Table 2. Primary Sources Table 3. Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 4. Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Volume and Revenue Market Size and CAGR of Manufacturers (2021 Versus 2025) Table 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) of Manufacturers (2021-2026) Table 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Manufacturers (2021-2026) Table 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue of Manufacturers (2021-2026) Table 9. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers (2021-2026) Table 10. Global Market Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) of Manufacturers (2021-2026) Table 11. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Ranking, 2024 VS 2025 VS 2026 Table 12. Global Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters Table 13. Global Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Type & Application Table 14. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Manufacturers Established Date Table 15. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 16. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 17. Manufacturers Mergers & Acquisitions, Expansion Plans) Table 18. Amgen Company Information Table 19. Amgen Business Overview Table 20. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 21. Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 22. Amgen Recent Developments Table 23. Mylan Company Information Table 24. Mylan Business Overview Table 25. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 26. Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 27. Mylan Recent Developments Table 28. Kashiv BioSciences Company Information Table 29. Kashiv BioSciences Business Overview Table 30. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 31. Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 32. Kashiv BioSciences Recent Developments Table 33. Pfizer Company Information Table 34. Pfizer Business Overview Table 35. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 36. Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 37. Pfizer Recent Developments Table 38. Fresenius Kabi Company Information Table 39. Fresenius Kabi Business Overview Table 40. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 41. Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 42. Fresenius Kabi Recent Developments Table 43. Coherus BioSciences Company Information Table 44. Coherus BioSciences Business Overview Table 45. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 46. Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 47. Coherus BioSciences Recent Developments Table 48. Sandoz Company Information Table 49. Sandoz Business Overview Table 50. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 51. Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 52. Sandoz Recent Developments Table 53. Italfarmaco SpA Company Information Table 54. Italfarmaco SpA Business Overview Table 55. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 56. Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 57. Italfarmaco SpA Recent Developments Table 58. Evive Biotech Company Information Table 59. Evive Biotech Business Overview Table 60. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 61. Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 62. Evive Biotech Recent Developments Table 63. Chugai Pharmaceutical Company Information Table 64. Chugai Pharmaceutical Business Overview Table 65. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 66. Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 67. Chugai Pharmaceutical Recent Developments Table 68. Jiangsu Hengrui Pharmaceuticals Company Information Table 69. Jiangsu Hengrui Pharmaceuticals Business Overview Table 70. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 71. Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 72. Jiangsu Hengrui Pharmaceuticals Recent Developments Table 73. Amoytop Biotech Company Information Table 74. Amoytop Biotech Business Overview Table 75. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 76. Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 77. Amoytop Biotech Recent Developments Table 78. Qilu Pharmaceutical Company Information Table 79. Qilu Pharmaceutical Business Overview Table 80. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 81. Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 82. Qilu Pharmaceutical Recent Developments Table 83. CSPC Baike Biopharma Company Information Table 84. CSPC Baike Biopharma Business Overview Table 85. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 86. CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 87. CSPC Baike Biopharma Recent Developments Table 88. SL Pharm Company Information Table 89. SL Pharm Business Overview Table 90. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 91. SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 92. SL Pharm Recent Developments Table 93. Lunan Pharmaceutical Company Information Table 94. Lunan Pharmaceutical Business Overview Table 95. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 96. Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio Table 97. Lunan Pharmaceutical Recent Developments Table 98. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Table 99. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2021-2026) & (K Units) Table 100. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2021-2026) Table 101. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region (2027-2032) & (K Units) Table 102. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Region (2027-2032) Table 103. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2021-2026) & (US$ Million) Table 104. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2021-2026) Table 105. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region (2027-2032) & (US$ Million) Table 106. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Region (2027-2032) Table 107. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 108. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 109. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 110. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 111. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 112. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 113. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 114. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 115. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 116. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 117. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 118. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 119. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 120. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 121. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 122. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 123. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 124. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 125. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 126. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 127. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 128. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2026) & (K Units) Table 129. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2027-2032) & (K Units) Table 130. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2026) & (US$ Million) Table 131. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2027-2032) & (US$ Million) Table 132. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2026) & (K Units) Table 133. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2027-2032) & (K Units) Table 134. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2026) Table 135. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2027-2032) Table 136. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2026) & (US$ Million) Table 137. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2027-2032) & (US$ Million) Table 138. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2026) Table 139. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2027-2032) Table 140. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2026) & (US$/Unit) Table 141. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2027-2032) & (US$/Unit) Table 142. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2026) & (K Units) Table 143. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2027-2032) & (K Units) Table 144. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2026) Table 145. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2027-2032) Table 146. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2026) & (US$ Million) Table 147. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2027-2032) & (US$ Million) Table 148. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2026) Table 149. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2027-2032) Table 150. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2026) & (US$/Unit) Table 151. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2027-2032) & (US$/Unit) Table 152. Key Raw Materials Table 153. Raw Materials Key Suppliers Table 154. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors List Table 155. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers List Table 156. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends Table 157. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers Table 158. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints Table 159. Authors List of This Report List of Figures Figure 1. Research Methodology Figure 2. Research Process Figure 3. Key Executives Interviewed Figure 4. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Image Figure 5. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue (US$ Million), 2021 VS 2025 VS 2032 Figure 6. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (2021-2032) & (US$ Million) Figure 7. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032) & (K Units) Figure 8. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price (US$/Unit) & (2021-2032) Figure 9. Lenograstim Product Image Figure 10. Pegfilgrastim Product Image Figure 11. Other Product Image Figure 12. Hospital and Clinic Product Image Figure 13. Pharmacy Product Image Figure 14. Other Product Image Figure 15. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Share by Manufacturers in 2025 Figure 16. Global Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters Figure 17. Global Top 5 and 10 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Players Market Share by Revenue in 2025 Figure 18. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 19. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region (US$ Million): 2021 VS 2025 VS 2032 Figure 20. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region in 2025 Figure 21. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region in 2025 Figure 22. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 23. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 24. North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 25. United States Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 26. Canada Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 27. Mexico Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 28. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 29. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 30. Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 31. Germany Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 32. France Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 33. U.K. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 34. Italy Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 35. Russia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 36. Spain Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 37. Netherlands Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 38. Switzerland Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 39. Sweden Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 40. Poland Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 41. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 42. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 43. Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 44. China Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 45. Japan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 46. South Korea Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 47. India Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 48. Australia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 49. Taiwan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 50. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 51. Southeast Asia Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 52. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 53. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 54. South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 55. Brazil Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 56. Argentina Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 57. Chile Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 58. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country in 2025 Figure 59. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Country (2021-2032) Figure 60. Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Country (2021-2032) Figure 61. Egypt Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 62. South Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 63. Israel Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 64. Türkiye Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 65. GCC Countries Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Growth Rate (2021-2032) & (US$ Million) Figure 66. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032) Figure 67. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032) Figure 68. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Type (2021-2032) Figure 69. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032) Figure 70. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032) Figure 71. Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price (US$/Unit) by Application (2021-2032) Figure 72. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Figure 73. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process Figure 74. Direct Comparison with Distribution Share Figure 75. Distributors Profiles Figure 76. Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges

Scope & coverage.

Types
  • Lenograstim
  • Pegfilgrastim
  • Other
Applications
  • Hospital and Clinic
  • Pharmacy
  • Other
Companies covered
  • Amgen
  • Mylan
  • Kashiv BioSciences
  • Pfizer
  • Fresenius Kabi
  • Coherus BioSciences
  • Sandoz
  • Italfarmaco SpA
  • Evive Biotech
  • Chugai Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Amoytop Biotech
  • Qilu Pharmaceutical
  • CSPC Baike Biopharma
  • SL Pharm
  • Lunan Pharmaceutical

Inside the report.

1 Preface
  1. 1.1 Scope of Report
  2. 1.2 Reasons for Doing This Study
  3. 1.3 Research Methodology
  4. 1.4 Research Process
  5. 1.5 Data Source
  6. 1.5.1 Secondary Sources
  7. 1.5.2 Primary Sources
2 Market Overview
  1. 2.1 Product Definition
  2. 2.2 Global Market Growth Prospects
  3. 2.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size (2021-2032)
  4. 2.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (2021-2032)
  5. 2.2.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Average Price (2021-2032)
  6. 2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Type
  7. 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
  8. 2.3.2 Lenograstim
  9. 2.3.3 Pegfilgrastim
  10. 2.3.4 Other
  11. 2.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) by Application
  12. 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
  13. 2.4.2 Hospital and Clinic
  14. 2.4.3 Pharmacy
  15. 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
  1. 3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Competitive Situation by Manufacturers (2021 Versus 2025)
  2. 3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales (K Units) of Manufacturers (2021-2026)
  3. 3.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue of Manufacturers (2021-2026)
  4. 3.4 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Average Price by Manufacturers (2021-2026)
  5. 3.5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Ranking, 2024 VS 2025 VS 2026
  6. 3.6 Global Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Manufacturing Sites & Headquarters
  7. 3.7 Global Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Product Type & Application
  8. 3.8 Global Manufacturers of Long-acting Granulocyte-Colony Stimulating Factor (G-CSF), Established Date
  9. 3.9 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market CR5 and HHI
  10. 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
  1. 4.1 Amgen
  2. 4.1.1 Amgen Company Information
  3. 4.1.2 Amgen Business Overview
  4. 4.1.3 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  5. 4.1.4 Amgen Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  6. 4.1.5 Amgen Recent Developments
  7. 4.2 Mylan
  8. 4.2.1 Mylan Company Information
  9. 4.2.2 Mylan Business Overview
  10. 4.2.3 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  11. 4.2.4 Mylan Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  12. 4.2.5 Mylan Recent Developments
  13. 4.3 Kashiv BioSciences
  14. 4.3.1 Kashiv BioSciences Company Information
  15. 4.3.2 Kashiv BioSciences Business Overview
  16. 4.3.3 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  17. 4.3.4 Kashiv BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  18. 4.3.5 Kashiv BioSciences Recent Developments
  19. 4.4 Pfizer
  20. 4.4.1 Pfizer Company Information
  21. 4.4.2 Pfizer Business Overview
  22. 4.4.3 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  23. 4.4.4 Pfizer Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  24. 4.4.5 Pfizer Recent Developments
  25. 4.5 Fresenius Kabi
  26. 4.5.1 Fresenius Kabi Company Information
  27. 4.5.2 Fresenius Kabi Business Overview
  28. 4.5.3 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  29. 4.5.4 Fresenius Kabi Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  30. 4.5.5 Fresenius Kabi Recent Developments
  31. 4.6 Coherus BioSciences
  32. 4.6.1 Coherus BioSciences Company Information
  33. 4.6.2 Coherus BioSciences Business Overview
  34. 4.6.3 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  35. 4.6.4 Coherus BioSciences Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  36. 4.6.5 Coherus BioSciences Recent Developments
  37. 4.7 Sandoz
  38. 4.7.1 Sandoz Company Information
  39. 4.7.2 Sandoz Business Overview
  40. 4.7.3 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  41. 4.7.4 Sandoz Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  42. 4.7.5 Sandoz Recent Developments
  43. 4.8 Italfarmaco SpA
  44. 4.8.1 Italfarmaco SpA Company Information
  45. 4.8.2 Italfarmaco SpA Business Overview
  46. 4.8.3 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  47. 4.8.4 Italfarmaco SpA Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  48. 4.8.5 Italfarmaco SpA Recent Developments
  49. 4.9 Evive Biotech
  50. 4.9.1 Evive Biotech Company Information
  51. 4.9.2 Evive Biotech Business Overview
  52. 4.9.3 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  53. 4.9.4 Evive Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  54. 4.9.5 Evive Biotech Recent Developments
  55. 4.10 Chugai Pharmaceutical
  56. 4.10.1 Chugai Pharmaceutical Company Information
  57. 4.10.2 Chugai Pharmaceutical Business Overview
  58. 4.10.3 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  59. 4.10.4 Chugai Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  60. 4.10.5 Chugai Pharmaceutical Recent Developments
  61. 4.11 Jiangsu Hengrui Pharmaceuticals
  62. 4.11.1 Jiangsu Hengrui Pharmaceuticals Company Information
  63. 4.11.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  64. 4.11.3 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  65. 4.11.4 Jiangsu Hengrui Pharmaceuticals Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  66. 4.11.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  67. 4.12 Amoytop Biotech
  68. 4.12.1 Amoytop Biotech Company Information
  69. 4.12.2 Amoytop Biotech Business Overview
  70. 4.12.3 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  71. 4.12.4 Amoytop Biotech Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  72. 4.12.5 Amoytop Biotech Recent Developments
  73. 4.13 Qilu Pharmaceutical
  74. 4.13.1 Qilu Pharmaceutical Company Information
  75. 4.13.2 Qilu Pharmaceutical Business Overview
  76. 4.13.3 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  77. 4.13.4 Qilu Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  78. 4.13.5 Qilu Pharmaceutical Recent Developments
  79. 4.14 CSPC Baike Biopharma
  80. 4.14.1 CSPC Baike Biopharma Company Information
  81. 4.14.2 CSPC Baike Biopharma Business Overview
  82. 4.14.3 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  83. 4.14.4 CSPC Baike Biopharma Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  84. 4.14.5 CSPC Baike Biopharma Recent Developments
  85. 4.15 SL Pharm
  86. 4.15.1 SL Pharm Company Information
  87. 4.15.2 SL Pharm Business Overview
  88. 4.15.3 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  89. 4.15.4 SL Pharm Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  90. 4.15.5 SL Pharm Recent Developments
  91. 4.16 Lunan Pharmaceutical
  92. 4.16.1 Lunan Pharmaceutical Company Information
  93. 4.16.2 Lunan Pharmaceutical Business Overview
  94. 4.16.3 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales, Revenue and Gross Margin (2021-2026)
  95. 4.16.4 Lunan Pharmaceutical Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Product Portfolio
  96. 4.16.5 Lunan Pharmaceutical Recent Developments
5 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Scenario by Region
  1. 5.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Region: 2021 VS 2025 VS 2032
  2. 5.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021-2032
  3. 5.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2021-2026
  4. 5.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Region: 2027-2032
  5. 5.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021-2032
  6. 5.3.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2021-2026
  7. 5.3.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Region: 2027-2032
  8. 5.4 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  9. 5.4.1 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  10. 5.4.2 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  11. 5.4.3 North America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  12. 5.4.4 United States
  13. 5.4.5 Canada
  14. 5.4.6 Mexico
  15. 5.5 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  16. 5.5.1 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  17. 5.5.2 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  18. 5.5.3 Europe Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  19. 5.5.4 Germany
  20. 5.5.5 France
  21. 5.5.6 U.K.
  22. 5.5.7 Italy
  23. 5.5.8 Russia
  24. 5.5.9 Spain
  25. 5.5.10 Netherlands
  26. 5.5.11 Switzerland
  27. 5.5.12 Sweden
  28. 5.5.13 Poland
  29. 5.6 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  30. 5.6.1 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  31. 5.6.2 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  32. 5.6.3 Asia Pacific Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  33. 5.6.4 China
  34. 5.6.5 Japan
  35. 5.6.6 South Korea
  36. 5.6.7 India
  37. 5.6.8 Australia
  38. 5.6.9 Taiwan
  39. 5.6.10 Southeast Asia
  40. 5.7 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  41. 5.7.1 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  42. 5.7.2 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  43. 5.7.3 South America Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  44. 5.7.4 Brazil
  45. 5.7.5 Argentina
  46. 5.7.6 Chile
  47. 5.8 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Facts & Figures by Country
  48. 5.8.1 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Market Size by Country: 2021 VS 2025 VS 2032
  49. 5.8.2 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Country (2021-2032)
  50. 5.8.3 Middle East and Africa Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Country (2021-2032)
  51. 5.8.4 Egypt
  52. 5.8.5 South Africa
  53. 5.8.6 Israel
  54. 5.8.7 Türkiye
  55. 5.8.8 GCC Countries
6 Segment by Type
  1. 6.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032)
  2. 6.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032) & (K Units)
  3. 6.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Type (2021-2032)
  4. 6.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Type (2021-2032)
  5. 6.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Type (2021-2032) & (US$ Million)
  6. 6.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Type (2021-2032)
  7. 6.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Type (2021-2032)
7 Segment by Application
  1. 7.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032)
  2. 7.1.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032) & (K Units)
  3. 7.1.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Market Share by Application (2021-2032)
  4. 7.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue by Application (2021-2032)
  5. 7.2.1 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales by Application (2021-2032) & (US$ Million)
  6. 7.2.2 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Revenue Market Share by Application (2021-2032)
  7. 7.3 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
  1. 8.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Value Chain Analysis
  2. 8.1.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Key Raw Materials
  3. 8.1.2 Raw Materials Key Suppliers
  4. 8.1.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Production Mode & Process
  5. 8.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Sales Channels Analysis
  6. 8.2.1 Direct Comparison with Distribution Share
  7. 8.2.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Distributors
  8. 8.2.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Customers
9 Global Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Analyzing Market Dynamics
  1. 9.1 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Trends
  2. 9.2 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Drivers
  3. 9.3 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Opportunities and Challenges
  4. 9.4 Long-acting Granulocyte-Colony Stimulating Factor (G-CSF) Industry Restraints
10 Report Conclusion
    11 Disclaimer

      GET THE RESEARCH

      Choose your license.

      Choose who needs access.
      All options are for this report and research series.

      Compare access permissions.

      Single User License
      One named user. Individual access.
      Multi User License
      Up to 5 users in the same department.
      Enterprise License
      Organization-wide access within the agreed license.

      Access applies to the purchased edition. Later editions are separate purchases.

      License options
      $2,950USD
      Buy now

      PDF by email within 3–5 working days after payment confirmation.

      Talk to an analyst
      APO Research
      Talk to an analyst